Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P17174 (
aspartate aminotransferase
)
14,872
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Previous reports, including our work, have shown that plasma beta-galactoside alpha2,6-sialyltransferase (
ST6Gal I
) activity is significantly increased in particular hepatopathological situations, suggesting that it may represent a sensitive biomarker for diagnosing hepatic diseases. So far, activity of
ST6Gal I
have been measured by using radioactive tracer method in place of measuring amount of
ST6Gal I
. However, this method is tangled and cannot exclude other sialyltransferase activities. Thus, simple and specific methods for measuring plasma
ST6Gal I
had been unavailable. Here, we developed two kinds of sandwich enzyme-linked immunosorbent assay (ELISA) systems that specifically detect the soluble cleaved form of
ST6Gal I
in plasma. In one sandwich ELISA, we detected rat specific sequence, EFQMPK, which is N-terminus of soluble
ST6Gal I
. In the other sandwich ELISA, we detected internal common sequence among rat, mouse and human
ST6Gal I
in plasma (M2 ELISA). Using the M2 ELISA, we observed that elevation of plasma
ST6Gal I
was much faster than elevation of plasma
aspartate aminotransferase
(
AST
) and alanine aminotransferase (ALT) in a carbon tetrachloride (CCl(4))-induced mouse liver injury model. Our data suggest that these ELISA systems are very useful tools for measuring plasma
ST6Gal I
, which represents a potential biomarker for diagnosing hepatic diseases.
...
PMID:Development of sandwich enzyme-linked immunosorbent assay systems for plasma beta-galactoside alpha2,6-sialyltransferase, a possible hepatic disease biomarker. 1904 88
